Information in this section applies to all of Minnesota's Health Care Programs (MHCP). Providers must contact the appropriate health plan for pharmacy information related to recipients in managed care organizations (MCO).
Federal Anti-Fraud Statutes
Pharmacies cannot use pharmaceutical manufacturers’ coupons, discounts or similar promotions to attract prescription business from Medical Assistance recipients. Federal anti-fraud and abuse provisions prohibit certain types of business transactions or arrangements, per Section 231(h) of HIPAA and the Office of Inspector General Special Fraud Alert, 59 Fed. Reg. 242; 1994. See Provider Requirements section for details.
How to Determine Drug Coverage
Use the NDC Search site (http://mn-its.dhs.state.mn.us/ndc/) to determine MHCP coverage of individual drug products.
Each listed drug product is assigned a unique 11-digit, 3-segment number, known as the National Drug Code (NDC). The first segment (5-digits) identifies the manufacturer or labeler of the drug, the second segment (4-digits) identifies the drug, and the third segment (2-digits) the package size. MHCP requires the 11-digit 5-4-2- format for billing or reporting a NDC. Use the NDC Format Conversion chart to convert a 10-digit NDC to an 11 digit NDC.
If a manufacturer is not listed as a participant in the federal Medicaid Drug Rebate Program, products from that manufacturer will not be covered by that MHCP program.
Payment for Prescribed Drugs
The maximum payment for any prescribed drug is the lower of the following:
Effective Aug. 1, 2011, Goold Health Systems (GHS) will be the MHCP contracted vendor to maintain the state maximum allowable cost (SMAC) list for generic drugs. Direct questions about the SMAC program or specific SMAC prices to GHS. To initiate a SMAC price review complete the MHCP SMAC Research Request Form (DHS-6406) (PDF) and fax it to the GHS Minnesota SMAC Helpdesk at:
Tamper-Resistant Prescription Blanks
The Appropriations Act of 2007-H. R. 2206—76 (PDF) states that payment will not be made for prescriptions in non-electronic form for Medical Assistance (MA) covered outpatient drugs in unless the prescription was executed on a tamper resistant prescription blank. This law does not affect E-prescribed, faxed or prescriptions phoned in to the pharmacy by the prescriber.
Effective Oct, 1, 2008, hand-written prescriptions must be executed on a tamper-resistant prescription blank with at least one characteristic from all three categories as outlined in the July 2008 NCPDP letter to Medicaid (PDF).
To dispense prescription drugs, an enrolled provider must meet at least one of the following criteria:
To be eligible for coverage, prescriptions must be written by an enrolled prescriber. Prescriptions written by non-enrolled providers are not covered under fee-for-service (FFS) MHCP.
The following enrolled providers may prescribe drugs within the scope of their profession:
Pharmacists may prescribe over-the-counter (OTC) medications to FFS or managed care (MCO) and MA recipients.
All MHCP recipients are eligible for a certain level of pharmacy and medical supply benefits. See Health Care Programs and Services for specific program coverage. Use MN–ITS Eligibility Request (270) to verify recipient eligibility and other insurance coverage. Programs with limited prescription drug coverage include the following:
Recipients eligible for both MHCP and Medicare Part D (dual eligibles) must select a Medicare Part D plan and receive most of their medications through their selected Medicare Part D plan. MHCP will only cover drugs excluded by law from Medicare Part D coverage.
When a recipient elects hospice coverage, bill outpatient drugs and medical supplies directly related to the terminal illness to the Hospice Provider. If prescription drugs or medical supplies are needed to treat a preexisting condition outside the scope or purpose of treating the terminal illness, follow the standard billing guidelines to bill for MA or MinnesotaCare recipients.
Most decisions regarding MHCP drug coverage are made at the federal level in accordance with Federal OBRA Laws of 1990. Those areas left to Minnesota's discretion are described in this chapter in the Pharmacy Service Limitations section. Please consult these documents for more information on drug coverage:
Responsibilities of the Drug Formulary Committee and Drug Utilization Review Board are outlined under the definitions section of this chapter.
The Minnesota Family Planning Program (MFPP) implemented July 1, 2006, provides family planning services and supplies for women and men ages 15 to 50. See Pharmacy Services, Confidentiality and billing instructions in Minnesota Family Planning Program section of the MHCP Provider Manual.
State law allows a pharmacist to administer flu vaccines to people age ten and older and all other vaccines to people who are age 18 and older under standing orders from a licensed physician or by written protocol with a physician provided that the pharmacist meets the following:
State law also requires that providers who administer flu vaccines to children ages 10-18 obtain the flu vaccine from the Minnesota Vaccines for Children Program (MNVFC)
For people 19 years old and older, providers must obtain immunizations and vaccines that are available from the Minnesota Department of Health (MDH) adult immunization and vaccine program.
MHCP does not pay for immunizations or vaccines that are available through the Minnesota Department of Health (MDH) at no cost to the provider.
The affiliated pharmacy is responsible for billing MHCP for the pharmacist-administered vaccine and administration fee using the correct CPT codes through their billing intermediary, on MN–ITS Interactive 837 Professional.
Bill drugs that are administered to a patient as part of a clinic or other outpatient visit to MHCP using the appropriate HCPCS code(s). See Physician and Professional Services section. Do not bill drugs administered during an outpatient visit through the pharmacy POS system. MHCP does not allow “brown-bagging” or “white-bagging” of prescription drugs administered in an office setting.
Pharmacies, including mail order pharmacies, who are providing the drugs for a clinic visit, should bill the clinic and not MHCP for the drugs dispensed. MHCP will make an exception only if a recipient has third-party liability and the third-party payer requires that the drugs be billed through the pharmacy benefit.
Pharmacies should not dispense drugs directly to a patient if the drugs are intended for use during a clinic or other outpatient visit.
The following policies apply to pharmacists prescribing OTC medications:
Example: If a pharmacist is dispensing two bisacodyl tablets for a one-time bowel preparation and the shelf price of the 12-count box of bisacodyl tablets is $3, submit $3 as the usual and customary price for the two tablets.
Example: A pharmacist is dispensing 20 tablets of loperamide for an acute diarrhea episode. The tablets come in a package of 40 tablets and the shelf price for the package is $12. Submit $6 (the pro-rated shelf price) as usual and customary. Alternatively, the pharmacist could dispense a smaller package size.
To verify if an over the counter (OTC) product is covered by MHCP, use our NDC Search or call the MHCP Provider Call Center with the NDC on the container, or reference the MHCP OTC Drugs or Excludable Drugs list: MS Excel or PDF format.
Specialty pharmaceuticals are defined as those used by a small number of recipients with complex and chronic diseases that require expensive and challenging drug regimens. The Minnesota Department of Human Services was granted legislative authority to negotiate Specialty Pharmacy Reimbursement Rates lower than the standard WAC plus 2%. Refer to the Specialty Drug List for current Specialty Pharmacy Reimbursement Rates (SMAC pricing).
The following are not covered:
MHCP does not allow automatic refills. Prescription refills are not eligible for payment without an explicit request from a recipient or authorized caregiver. The pharmacy provider may not contact the recipient in an effort to initiate a refill unless it is part of a good faith clinical effort to assess the recipient’s medication regimen.
A nurse or other authorized agent of the facility may initiate a request for refill for a recipient residing in a skilled nursing facility, group home or assisted living arrangement.
Cycle fills are only allowed for enrolled unit dose dispensing pharmacies for recipients residing in skilled nursing facilities.
Do not submit prior authorization (PA) requests for the above-listed MHCP noncovered drugs. Authorization cannot be granted.
Updated lists of all drugs requiring prior authorization are posted on the MHCP Pharmacy web page. Authorization requests with incomplete information cannot be processed.
Effective Jan. 1, 2011, pharmacies and prescribing providers must submit all drug PA requests for outpatient prescription drugs and physician-administered drug that require authorization to Health Information Designs (HID) the MHCP Prescription Drug PA Review Agent, by phone at 866-205-2818 or by fax at 866-648-4574.
When the prescriber initiates the PA request by phone or by fax supply the following:
The MHCP Prescription Drug PA Review Agent will make outbound calls to the pharmacy to determine the NDC and pharmacy NPI, as needed.
When the pharmacy initiates the PA request by phone or fax, the pharmacist may have to obtain some information from the prescriber, as listed above consistent with Minnesota Rules 6800.3110, subp. 2a: "Minimum information required; Medicaid patients."
The MHCP Prescription Drug PA Review Agent call center hours are 8 a.m. to 7 p.m., Monday through Friday
Pharmacists may dispense up to a 72-hour supply of a covered medication outside the regular business hours of the MHCP Prescription Drug PA Review Agents. Contact the MHCP Prescription Drug PA review agent during regular business hours for a retroactive authorization for the 72-hour supply.
The MHCP Prescription Drug PA Review Agent will not authorize the 72-hour supply if the drug dispensed is never covered. Additional supplies will not be approved unless criteria are met.
DHS has the authority to require authorization for new drugs for 180 days post-market introduction without formulary review.
For drugs dispensed and billed by a pharmacy, the pharmacist is responsible for obtaining the prior authorization number from the MHCP prescription drug PA review agent or from a prescriber who has received it from the MHCP prescription drug PA review agent. The pharmacist may have to obtain some information from the prescriber, such as diagnosis, consistent with Minnesota Rules 6800.3110, subp. 2a: "Minimum information required; Medicaid patients."
For Medicaid patients, the pharmacy must make a reasonable effort to obtain, record, and maintain at least the following information:
This documentation is not required for residents of a licensed nursing home when a consultant pharmacist is performing regular drug regimen reviews.
The prescriber must authorize and approve refill prescriptions as consistent with accepted pharmacy practice. The pharmacist who refills the prescription must document and initial refills in the prescription file.
The Drug Formulary Committee reviewed and accepted the following prior authorization criteria for payment of brand name medications when a generic is available and a State Maximum Allowable Cost (SMAC) applies:
Include the name and NPI number of the MHCP prescribing physician, the NDC number, and the NPI number of the dispensing MHCP pharmacy.
When submitting claims, dispensing providers must use code 01: Substitution Not Allowed by Provider and the authorization number.
An exception to this policy is when a generic drug has a higher net cost to the State than the brand name drug. When this occurs, MHCP may prefer the brand name drug over the generic until the generic product is available at a reduced cost. When DHS prefers the brand to the generic, the prescriber is not required to write “DAW–brand medically necessary” on the prescription or enter “Brand Medically Necessary” in the “Prescriber note to Pharmacy” field. When a new generic drug becomes available, use our NDC Search or call the MHCP Provider Call Center to determine if the generic drug is under authorization requirements.
Maximum Allowable Cost (MAC) price limitations do not apply if the prescriber has certified that a particular brand is medically necessary and has met the prior authorization criteria. If a prescription is "DAW–brand necessary," but the prescribed drug manufacturer is not a participant in the Federal Drug Rebate Program, the drug is not covered.
Contact the MHCP Provider Call Center at 651-431-2700 or 800-366-5411 for a refill-too-soon override in the situations listed below:
The MHCP Provider Call Center cannot issue a prior authorization or an override for drugs requiring an authorization due to preferred drug list status or clinical criteria.
Pharmacies must use their NCPDP D.0 POS (point of sale) to bill for prescription drugs. Pharmacies should not bill for drugs administered in a clinic.
Review MHCP general Third Party Liability (TPL) policy in the Billing Policy section of the Provider Manual.
Bill primary health insurance plans and receive payment to the fullest extent possible before billing MHCP. Private health care coverage is primary to MHCP and must be used first and according to the rules of the specific plan. You are responsible for the following:
Do not accept cash payment from a recipient, or from someone paying on behalf of the recipient, for any MHCP covered prescription drug.
A pharmacy may accept cash payment for a noncovered prescription drug if all of the following apply:
A pharmacy may accept cash payment for a controlled substance or for a gabapentin prescription only if the pharmacy has received authorization from MHCP to do so on the date of service. To be considered for cash payment authorization, the prescriber must contact the MHCP Provider Call Center and provide rationale why covered alternatives are not viable options for the recipient.
If a recipient’s MHCP eligibility status is in question and the recipient offers cash payment for prescriptions, the pharmacy must verify eligibility through MN–ITS or EVS. If the person does not have coverage through MHCP, you may charge that person and accept cash as payment. If the recipient is covered by MHCP, do not accept cash payment from the recipient for the prescription if the patient is enrolled in the restricted recipient program or the product requested is a controlled substance or gabapentin.
All required fields must be completed on the NCPDP claim for the claim to process. Some fields are mandatory while other fields are optional. Optional fields may become required only when reporting situational information, such as coordination of benefits or other payments or adjustments made on a claim.
In the Usual and Customary Charge field, enter the amount you would charge cash customers, less any sales tax and other discounts, coupons, insurance write-offs or price reduction adjustment.
Example: The pharmacy bills the TPL (other insurance) their usual and customary amount of $100. The TPL indicates there is a provider write-off adjustment of $20 on this claim. The TPL pays $60 with a $20 subscriber copay amount due. The pharmacy would bill MHCP $80 ($100 usual and customary, less the $20 provider write-off adjustment), report the $60 TPL payment in other payer amount paid field and enter the $20 copay amount in the gross amount due field.
Use the following criteria when submitting your usual and customary charge:
Providers may need to override their system's usual and customary charge manually to prevent over-billing.
Pharmacies must follow the NCPDP Implementation Guide when submitting claims with coordination of benefits from more than one health plan or provider. Complete all applicable fields correctly and appropriately. Failure to do so will cause denial of claims or recovery of payments.
Refer to the Minnesota Medicaid Version D.0 NCPDP Payer Sheet (PDF) for specific billing instructions.
POS claims are screened by DHS online edits that check recipient data and alert pharmacists to potential drug conflicts. This screening process, referred to as ProDUR, occurs at the time of POS transmission. Claims in conflict with ProDUR edits are identified by a series of DUR conflict, intervention and outcome codes and may be overridden by the pharmacist. The only POS edits that a pharmacist can override are those relating to DUR. A pharmacist may override a ProDUR edit only if there is a valid reason for doing so. Refer to the Non-Controlled and Controlled Substances linked charts in the "Policies for Handling Refill-Too-Soon Override and Authorization Requests" section to determine if an override request is appropriate.
Paid Claim: Some DUR conflict codes are posted for informational purposes only and allow claims to be paid.
If it is in the recipient's best medical interest to fill the prescription, the pharmacist may override the denial. Enter the appropriate intervention and outcome codes in the corresponding field and resubmit the claim using POS. To override a denial code, do the following:
MN–ITS is a no-cost online DHS web-based HIPAA-compliant billing, inquiry and communication tool. Computer and internet access are required. For more information about using MN–ITS, refer to the following:
The 2007 Minnesota Legislation passed new regulations requiring all health care providers and payers to submit transactions electronically by 2009. As of July 15, 2009, MHCP no longer accepts paper claims.
Use HCPCS code G9012 for case management service for the specialized care management service required to ensure the safety of the recipients receiving clozapine. Clozapine management services consist of the following:
Refer to the following when billing for clozapine case management:
Note: The blood test is separately reimbursable for a Medicaid–certified laboratory.
Some MHCP recipients may have a copay or spenddown responsibility for products and service.
An ICD diagnosis code must be included on claims for certain drugs. The pharmacist must verify the diagnosis with the prescriber before submitting a claim. Review: Drugs requiring a diagnosis code.
Enter the ICD diagnosis code in the Diagnosis Code field on POS or on MN–ITS Interactive Pharmacy (NCPDP) electronic format.
Pharmacies that dispense medically necessary medical supplies and equipment, such as enteral nutritional products, incontinence products, gauze pads or walkers, must submit the claim to MHCP using the Healthcare Common Procedure Code System (HCPCS) code set and, in some cases, a modifier. A modifier further defines the product or service by indicating for example: if the item is new, a rental or being repaired, if the product or service warrants additional pricing, etc.
For diabetic supplies, see Point of sale Diabetic Testing Supply Program.
Contact your software vendor or billing intermediary for their specific billing instructions for medical supplies and equipment. In many cases, the billing intermediary will convert a NDC to a HCPCS code for their billing clients.
Use MN–ITS 837P to bill for medical supplies and equipment. Refer to the MN–ITS User Guide for DME, Medical Supplies, Prosthetic and Orthotic Service for billing instructions.
Submit authorization requests with the required documentation to the authorization medical review agent. Submit authorization requests via MN–ITS, fax or mail.
Refer to the Equipment & Supplies section of this manual for coverage criteria and billing instructions. Find links to Medical Supply Related Lists and Prior Authorization Forms on the MHCP Enrolled Providers - Equipment and Supplies homepage.
All pharmacy claims submitted to DHS must identify the 11-digit NDC printed on the stock container in which the drug was purchased.
A pharmacy may not dispense a repackager's drug and then bill DHS using the original manufacturer's NDC.
Medicaid does not cover most drugs distributed by repackagers because the repackager has not signed a rebate agreement with CMS.
Use HCPCS code G9012 as a case management service for patient monitoring associated with the administration of Clozaril (clozapine). Submit claims using MN–ITS Professional (837P).
All pharmacy claims must include the National Provider Identifier (NPI) of the prescribing provider, or in certain rare situations, an alternate NPI may be used as outlined below:
Enter the prescribing provider NPI or the appropriate alternate NPI in the corresponding POS field or on MN–ITS Interactive Pharmacy (NCPDP) electronic format.
MHCP enrolled prescribing provider NPIs are in the NPI and UPMI list published on the secure MN–ITS Interactive Welcome page. (MN–ITS login is required)
Pharmacy providers should not reverse claims on POS for recipients who have had a change in their spenddown amount, program coverage or eligibility. DHS will make the adjustment automatically.
If a replacement claim does not appear on your next RA within two weeks of the spenddown or eligibility change, contact the Provider Call Center at 651-431-2700 or 800-366-5411.
Actual Acquisition Cost: The net cost of a drug to the dispenser; this includes quantity, volume, and special discounts but does not include cash or time discounts. The commissioner estimates the acquisition cost of a drug to be Wholesale Acquisition Cost (WAC), plus two percent.
Cash Discount: A reduction in price that occurs when cash accompanies the order for merchandise.
Compounded Prescription: A prescription prepared in accordance with Minnesota Rules 6800.3100.
Dispensing Date: The actual date the entire quantity was dispensed. For drugs dispensed in unit dose containers, the last dispensing date of the calendar month must be used as the dispensing date on the claim form.
Dispensing Fee: The amount allowed for the pharmacy service in dispensing the prescribed drug.
Drug Efficacy Study Implementation (DESI) Drugs: Federal Food and Drug Administration (FDA) designations related to "substantial evidence" of effectiveness. DESI drugs were introduced to the market between 1937 and 1962, during which time manufacturers did not have to show that their products were effective. Federal Medicaid statutes prohibit state Medicaid agencies from paying for these drugs. Examples include Midrin and Anusol HC suppositories.
Dual Eligibility: Individuals entitled to Medicare Part A/Part B and eligible for some form of Medicaid benefit.
Federal Drug Rebate Program: Established by the federal statute referred to as OBRA 90, requires manufacturers to sign a rebate agreement with the federal Center for Medicare and Medicaid Services (CMS) in order to have their products covered for Medicaid recipients. State Medicaid agencies administer the program and collect rebates from the manufacturers.
Generically Equivalent Drug: A drug product that, in the pharmacist's professional judgment, is safely interchangeable with the prescribed drug.
Legend drug: A drug that is required by federal law to bear one of the following statements: “Caution: Federal law prohibits dispensing without prescription” or “Rx only.”
Maintenance Drug: A prescribed drug that a recipient uses for a period greater than two consecutive months.
Maximum Allowable Cost (MAC): The highest drug ingredient reimbursement that will be allowed for drugs designated by CMS or by DHS as multisource. Federally designated reimbursement values are referred to as federal upper limits (FUL). These reimbursement values are updated on an intermittent basis and are available on the DHS Web site in a PDF format.
Pharmacist: An individual with a currently valid license issued by a state board of pharmacy to practice pharmacy.
Pharmacy: An established place of business, licensed by a state board of pharmacy, in which prescriptions, drugs, medicines, chemicals, and poisons are prepared, compounded, dispensed, vended, or sold to or for the use of patients and from which related clinical pharmacy services are delivered.
Pharmacy Service: The dispensing of drugs, counseling, concurrent DUR and other activities as described in MS 151.01, subd. 27, or as performed by a dispensing physician.
Point of Sale (POS): Software used to submit a pharmacy claim
Prescribed Drug: A drug as defined in MS 151.01, subd. 5. Ordered by a practitioner who is licensed to prescribe.
Presumptive Eligibility: A short-term period of eligibility that is determined at the point of service by the participating provider. The presumptive eligibility period begins the first day of the month that the participating provider makes the presumptive eligibility determination and continues through a minimum of 30 days after the date of application. Individuals found presumptively eligible may receive services immediately.
Quantity Discount: A price reduction that is dependent on the size or number of items ordered (e.g., a discount to the purchaser for buying drugs packaged in thousands rather than hundreds, or a discount for buying "x" units when either no discount or a lesser discount will apply if fewer than "x" units are ordered).
Reimbursement rates: The DHS reimbursement rate for most drugs without a generic equivalent is the lower of usual and customary or wholesale acquisition cost (WAC) plus two percent. For independent rural pharmacies in Minnesota, the reimbursement rate is the lower of usual and customary or WAC plus four percent.
Shelf Price: The price charged by a provider for a product when that product is sold to the public in the original, unopened manufacturer's container. Temporary sale prices or advertised markdowns with time limitations do not apply to shelf price.
Time Discount: A reduction in price when payment is made within a short time (not to exceed 10 days) after receipt of the merchandise; this definition will not apply to large volumes or quantities of drugs that are ordered and then received in small increments over a specified period with payment made for each increment after it is needed.
Usual and Customary: Refers to an amount billed by a provider, meaning provider's charge to the type of payer that constitutes the largest share of their business. For this definition, payer means a third party or persons who pay for health services by cash, check or charge account. See Minnesota Rules 9505.0175, subp.49
Volume Discount: Sometimes synonymous with quantity discount but it may also be a reduction in price based on the monetary volume of an invoice (e.g., 10% reduction for an order of $500 or more).
The Drug Formulary Committee (DFC) is charged with reviewing and recommending which drugs require authorization. The DFC also reviews over the counter (OTC) drugs for which coverage is optional under federal and state law (for possible inclusion in the Medicaid fee-for-service formulary).
The DFC is comprised of four physicians, four pharmacists, and a consumer representative. DFC meetings must hold a public forum and public comments are taken for an additional 15 days following a DFC recommendation to require prior authorization for a drug. The Department of Human Services (DHS) provides the DFC with information regarding the impact of placing a drug on required prior authorization status will have on the quality and cost of patient care.
The Drug Utilization Review (DUR) Board selects specific drug entities or therapeutic classes to be targeted for provider and recipient educational interventions, and provides guidelines for their use.
The nine-member DUR Board is composed of at least three, but not more than four, licensed physicians, at least three licensed pharmacists and one consumer representative, with the remaining members licensed health care professionals with clinically appropriate knowledge in prescribing, dispensing, and monitoring outpatient drugs. DUR Board meetings are open to the public.
Minnesota Statutes 151 (chapter – Pharmacy)
Minnesota Statutes 151.01, subd. 5, 27 and 49 (Definitions)
Minnesota Statutes 256B.0625, subd.13a-13g (Covered Services – Drugs)
Minnesota Rules 6800 (Chapter-Pharmacies and Pharmacists)
Minnesota Rules 6800.2700 (Return of drugs and devices)
Minnesota Rules 6800.3100 (Compound and Dispensing)
Minnesota Rules 6800.3110, subp. 2a (Patient Medication Profiles)
Minnesota Rules 9505.0175, subp. 49 (Usual and Customary)
Minnesota Rules 9505.0340 (Pharmacy Services)
Minnesota Rules 9505.5000 to 9505.5105 (Prior Authorization Applicability)
42 CFR 440.120(a)
Title XIX, Section 1927 of the Social Security Act (Payment for Covered Outpatient Drugs)
Title,XII, Section 483.10 (Resident rights)